跳到正文
原文
The Lancet 柳叶刀· Biree Andemariam, Kevin H M Kuo, Farjah H Algahtani, Salam Al Kindi, Kenneth I Ataga, Pablo Bartolucci, Andrew Campbell, Raffaella Colombatti, Alexander K Glaros, Kaoutar Hafraoui, Modupe Idowu, Seethal A Jacob, Clarisse L C Lobo, Obiageli E Nnodu, Lucas Otieno, Wally R Smith, Swee Lay Thein, Eduard J van Beers, Sarah Gheuens, Brooke Hensley, Abdulafeez Oluyadi, Kareem Osman, Asif Pathan, Spurthi Patil, Tao Song, Amber M Yates, Ahmar U Zaidi, Caterina Minniti, Miguel R Abboud, RISE UP Investigators·· 28 天前AI 评分51

Mitapivat 治疗镰状细胞病的 III 期 RISE UP 随机双盲安慰剂对照试验

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial

AI 导读

《The Lancet》发表了 RISE UP III 期随机双盲、全球、安慰剂对照试验,评估口服丙酮酸激酶激活剂 mitapivat 在镰状细胞病患者中的疗效与安全性。作者在摘要中提出,该药通过改善溶血性贫血的新机制,可能成为便捷的疾病修饰治疗手段。本次材料仅提供摘要,未给出具体结果数据。

来源:The Lancet 柳叶刀 · thelancet.com